Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Director Dayton Misfeldt bought 400,000 shares of the stock in a transaction on Friday, October 27th. The shares were acquired at an average price of $2.00 per share, with a total value of $800,000.00. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink.
COPYRIGHT VIOLATION NOTICE: “Sunesis Pharmaceuticals, Inc. (SNSS) Director Buys $800,000.00 in Stock” was published by Community Financial News and is the property of of Community Financial News. If you are accessing this story on another website, it was illegally stolen and republished in violation of US & international copyright and trademark law. The correct version of this story can be read at https://www.com-unik.info/2017/11/02/sunesis-pharmaceuticals-inc-snss-director-buys-800000-00-in-stock.html.
A number of institutional investors have recently added to or reduced their stakes in SNSS. Wells Fargo & Company MN raised its stake in Sunesis Pharmaceuticals by 77.4% during the second quarter. Wells Fargo & Company MN now owns 41,851 shares of the biopharmaceutical company’s stock worth $113,000 after acquiring an additional 18,254 shares in the last quarter. Virtu KCG Holdings LLC acquired a new position in Sunesis Pharmaceuticals during the second quarter worth $208,000. Renaissance Technologies LLC raised its stake in Sunesis Pharmaceuticals by 1.1% during the first quarter. Renaissance Technologies LLC now owns 111,811 shares of the biopharmaceutical company’s stock worth $458,000 after acquiring an additional 1,230 shares in the last quarter. Sphera Funds Management LTD. raised its stake in Sunesis Pharmaceuticals by 54.6% during the second quarter. Sphera Funds Management LTD. now owns 193,212 shares of the biopharmaceutical company’s stock worth $522,000 after acquiring an additional 68,212 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in Sunesis Pharmaceuticals by 4.1% during the second quarter. Vanguard Group Inc. now owns 605,759 shares of the biopharmaceutical company’s stock worth $1,635,000 after acquiring an additional 23,819 shares in the last quarter. Hedge funds and other institutional investors own 57.56% of the company’s stock.
Several analysts have weighed in on SNSS shares. Zacks Investment Research upgraded shares of Sunesis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.50 target price for the company in a research note on Thursday, August 24th. Cantor Fitzgerald reiterated a “hold” rating and set a $3.00 target price on shares of Sunesis Pharmaceuticals in a research note on Wednesday, September 27th. Finally, ValuEngine lowered shares of Sunesis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st.
Sunesis Pharmaceuticals Company Profile
Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).
What are top analysts saying about Sunesis Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Sunesis Pharmaceuticals Inc. and related companies.